Factors associated with treatment outcomes of patients with drug-resistant tuberculosis in China: A retrospective study using competing risk model

• Published in: Frontiers in public health 2022-09, Vol.10, p.906798-906798
• Main Authors: Li, Zhiwei, Lai, Keng, Li, Tiegang, Lin, Zhuochen, Liang, Zichao, Du, Yuhua, Zhang, Jinxin
• Format: Article
• Language: English
• Subjects: China - epidemiology; competing risk; drug-resistant tuberculosis; factor; Humans; Lost to Follow-Up; LTFU; Public Health; Retrospective Studies; Treatment Outcome; treatment outcomes; Tuberculosis, Multidrug-Resistant - drug therapy; Tuberculosis, Multidrug-Resistant - epidemiology
• ISSN: 2296-2565; 2296-2565
• DOI: 10.3389/fpubh.2022.906798

Drug-resistant tuberculosis remains a serious public health problem worldwide, particularly in developing countries, including China. This study determined treatment outcomes among a cohort in Guangzhou, China, and identified factors associated with them. We initiated a retrospective study using drug-resistant TB data in Guangzhou from 2016 to 2020, managed by Guangzhou Chest Hospital. A competing risk model was used to identify the factors associated with treatment failure and death, as well as loss to follow-up (LTFU). A total of 809 patients were included in the study, of which 281 were under treatment. Of the remaining 528 who had clear treatment outcomes, the number and proportion of treatment success, treatment failure, death, and LTFU were 314 (59.5%), 14 (2.7%), 32 (6.0%), and 168 (31.8%), respectively. Being older and having cavities involving the upper lungs were risk factors for treatment failure and death, while non-Guangzhou household registration and interprovincial mobility were risk factors associated with LTFU. Treatment failure and death were significantly associated with cavitation in the lungs, and LTFU was significantly associated with household registration and geographical mobility. Early identification of factors associated with different treatment outcomes is extremely important for policymakers, health experts, and researchers to implement appropriate strategies and measures to treat and manage the TB-infected population in China.